IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...
SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...
IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...
BOSTON, Sept. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary ...
Edwards Lifesciences Corporation EW recently gained CE Mark for its PASCAL Precision transcatheter valve repair system used to treat mitral and tricuspid regurgitation. The PASCAL Precision system is ...
The SAPIEN M3 system received CE Mark in April 2025, making it the world’s first approved transfemoral transcatheter mitral ...
The Sapien M3 device is the first approved mitral regurgitation treatment to use a transseptal approach, Edwards said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback